2:41
Immunotherapy in AML: azacitidine plus checkpoint inhibitors
Naval Daver
1:22
ALL: recent immunotherapeutic developments
Ryan Cassaday
1:27
CAR T-cells in ALL: an overview
Oliver Ottmann
2:22
New strategies for durable remission in MM
Niels van de Donk
2:40
Monoclonal antibodies: the future of MM treatment?
Faith Davies
2:12
T-cell redirecting therapies for R/R multiple myeloma
Niels van de Donk
3:01
MM treatment in the US vs. Europe: multi-drug regimens & cellular therapies
Ola Landgren
5:35
Contemporary designs for multiple myeloma treatment
Gareth Morgan
2:24
Novel ALL treatment strategies: blinatumomab
Elias Jabbour
1:48
Novel CLL therapy highlights from ASH 2017
Anthony Mato
2:01
AML: data to look forward to in 2018 and beyond
Richard Stone
9:41
Exciting new developments in multiple myeloma
Daniel Auclair et al.
1:52
The future is bright for hematological oncology: promising areas for 2018 and beyond
Kenneth Anderson
1:42
Venetoclax resistance and alternative treatments in CLL
John Gribben
11:24
The future of immunotherapy in multiple myeloma
Hearn Cho et al.
2:28
Game-changing drug classes for multiple myeloma
Gareth Morgan
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals